ATS 2021, News
Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.
ATS 2022
TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.
CHEST 2022
Post hoc analysis of the VENTURE/TRAVERSE trials assessed dupilumab efficacy in patients with severe asthma requiring varying levels of oral corticosteroids at baseline.
AAAAI 2021, News
Patients with asthma who depend on oral corticosteroids (OCS) may be able to reduce the dependence or eliminate the use of OCS altogether with benralizumab.
CHEST 2021, News
A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes.
ATS 2021, News
Long-term treatment of oral corticosteroid (OCS)-dependent asthma with dupilumab has shown efficacy in weaning off OCS while improving lung function.
CHEST 2022
Investigators explored the value of treating patients with bronchiolitis in primary Sjogren’s Syndrome using inhaled corticosteroids and long-acting beta agonists.
ACAAI 2022
The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.
AAO-HNS 2021
The most common presenting complaints included shortness of breath, rhinorrhea, and hoarseness.
AAAAI 2021, News
Active eosinophilic esophagitis appears to be associated with lower lung function and increased asthma severity in children with comorbid asthma.